Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) Director Jason Rhodes sold 426,412 shares of the company's stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $26.20, for a total transaction of $11,171,994.40. Following the completion of the sale, the director directly owned 751,411 shares in the company, valued at approximately $19,686,968.20. The trade was a 36.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Dyne Therapeutics Stock Performance
Shares of DYN stock opened at $26.15 on Tuesday. The stock has a market cap of $4.88 billion, a PE ratio of -7.85 and a beta of 1.07. The business has a 50-day simple moving average of $23.02 and a 200-day simple moving average of $19.55. The company has a quick ratio of 12.02, a current ratio of 12.02 and a debt-to-equity ratio of 0.28. Dyne Therapeutics, Inc. has a 52-week low of $11.65 and a 52-week high of $27.31.
Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.33). On average, equities analysts expect that Dyne Therapeutics, Inc. will post -3.37 EPS for the current year.
Institutional Trading of Dyne Therapeutics
A number of hedge funds and other institutional investors have recently modified their holdings of DYN. Creative Planning boosted its position in shares of Dyne Therapeutics by 6.8% during the 3rd quarter. Creative Planning now owns 15,527 shares of the company's stock valued at $196,000 after acquiring an additional 986 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Dyne Therapeutics by 26.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,940 shares of the company's stock valued at $136,000 after purchasing an additional 1,440 shares during the period. Hilton Head Capital Partners LLC acquired a new stake in Dyne Therapeutics during the first quarter worth about $26,000. Caxton Associates LLP increased its position in Dyne Therapeutics by 10.9% during the second quarter. Caxton Associates LLP now owns 16,599 shares of the company's stock worth $158,000 after purchasing an additional 1,627 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC raised its stake in Dyne Therapeutics by 102.1% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company's stock worth $95,000 after purchasing an additional 2,465 shares during the period. 96.68% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several equities analysts have recently weighed in on DYN shares. Royal Bank Of Canada raised their price target on shares of Dyne Therapeutics from $30.00 to $35.00 and gave the stock an "outperform" rating in a research note on Thursday, July 30th. Sanford C. Bernstein upped their price objective on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the company a "market perform" rating in a research note on Wednesday, May 13th. Evercore set a $33.00 price objective on shares of Dyne Therapeutics in a report on Friday, May 15th. Cantor Fitzgerald assumed coverage on shares of Dyne Therapeutics in a research note on Thursday, July 23rd. They issued an "overweight" rating on the stock. Finally, Morgan Stanley lowered their target price on Dyne Therapeutics from $47.00 to $45.00 and set an "overweight" rating on the stock in a report on Friday, July 31st. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, Dyne Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $34.42.
Read Our Latest Research Report on DYN
Dyne Therapeutics Company Profile
(
Get Free Report)
Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company's proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne's lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.
Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
